The trajectory of companies tied to Viagra's history presents a complex investment landscape. While the initial surge generated substantial gains, generic alternatives have significantly eroded revenue. Investing in associated pharmaceutical companies now requires a careful assessment of intellectual property safeguards, evolving healthcare trends